VIENNA — Combining the SGLT2 inhibitor empagliflozin with finerenone , a nonsteroidal mineralocorticoid receptor antagonist (MRA), markedly and durably reduced albuminuria in patients with both chronic kidney disease (CKD) and type 2 diabetes (T2D), the CONFIDENCE trial showed in findings that offer hope of a long-term improvement in outcomes.

In the trial, 70% of patients on both therapies achieved the American Diabetes Association recommended urinary albumin -to- creatinine ratio (UACR) reduction target of > 30%.

“Since UACR is a key mediator of kidney and cardiovascular outcomes, these results are highly relevant for clinical decision-making,” said lead researcher Rajiv Agarwal, MD, MS, professor emeritus of medicine, Indiana University School of Medicine, Indianapolis.

T

See Full Page